LianMedical (OTCPK: LIAN.Y)
Health Care · Biotechnology · US
$0.04
-24.00% today · -38.6% 1Y
LianMedical (OTCPK: LIAN.Y) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.79M and employs 163 people.
Over the last twelve months the share price has lost 38.6%, trading between 0.02 and 0.18.
Tweenvest scores LianMedical across four factors: quality 27/100. Its strongest factor is quality.
LIAN.Y price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.79M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.82
- Dividend yield
- —
- Beta (5Y)
- 0.13
- 52-week high
- $0.18
- 52-week low
- $0.02
- Avg volume (3M)
- —
- Shares outstanding
- 108.17M
- Employees
- 163
- Next earnings
- —
About LianMedical
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
- Founded
- 2019
- Listed since
- Nov 1, 2021
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.